DE69112207D1 - "walk-through"-mutagenese. - Google Patents

"walk-through"-mutagenese.

Info

Publication number
DE69112207D1
DE69112207D1 DE69112207T DE69112207T DE69112207D1 DE 69112207 D1 DE69112207 D1 DE 69112207D1 DE 69112207 T DE69112207 T DE 69112207T DE 69112207 T DE69112207 T DE 69112207T DE 69112207 D1 DE69112207 D1 DE 69112207D1
Authority
DE
Germany
Prior art keywords
antibodies
libraries
amino acids
mutants
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69112207T
Other languages
English (en)
Other versions
DE69112207T2 (de
Inventor
Roberto Crea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioren LLC
Original Assignee
Roberto Crea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Crea filed Critical Roberto Crea
Application granted granted Critical
Publication of DE69112207D1 publication Critical patent/DE69112207D1/de
Publication of DE69112207T2 publication Critical patent/DE69112207T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
DE69112207T 1990-04-05 1991-04-05 "walk-through"-mutagenese. Expired - Lifetime DE69112207T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50531490A 1990-04-05 1990-04-05
PCT/US1991/002362 WO1991015581A1 (en) 1990-04-05 1991-04-05 Walk-through mutagenesis

Publications (2)

Publication Number Publication Date
DE69112207D1 true DE69112207D1 (en) 1995-09-21
DE69112207T2 DE69112207T2 (de) 1996-03-28

Family

ID=24009833

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69112207T Expired - Lifetime DE69112207T2 (de) 1990-04-05 1991-04-05 "walk-through"-mutagenese.

Country Status (8)

Country Link
US (3) US5798208A (de)
EP (1) EP0527809B1 (de)
JP (2) JP4251406B2 (de)
AT (1) ATE126535T1 (de)
CA (1) CA2079802C (de)
DE (1) DE69112207T2 (de)
ES (1) ES2078518T3 (de)
WO (1) WO1991015581A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194807A1 (en) * 1992-11-02 2003-10-16 Roberto Crea Walk-through mutagenesis
EP0695353B1 (de) * 1993-04-09 2001-12-12 Catalytic Antibodies, Inc. Selektion von genen katalytischer antikörper
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5683987A (en) * 1994-07-12 1997-11-04 The Board Of Regents Of The University Of Nebraska Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
US6063562A (en) * 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
US5602021A (en) * 1994-12-29 1997-02-11 Catalytic Antibodies, Inc. Method for generating proteolytic enzymes specific against a selected peptide sequence
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6537776B1 (en) * 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
AU5760698A (en) * 1996-12-20 1998-07-17 Unilever Plc Enzymatic bleach composition
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
DE19731990A1 (de) * 1997-07-25 1999-01-28 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung und Identifizierung von neuen Hydrolasen mit verbesserten Eigenschaften
US6670127B2 (en) * 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
CA2319114A1 (en) * 1998-01-30 1999-08-05 Donald L. Heefner Gene regulator fusion proteins and methods of using the same for determining resistance of a protein to a drug targeted thereagainst
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US20090130718A1 (en) * 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
MXPA00009723A (es) * 1999-02-04 2003-09-22 Diversa Corp Generacion no estocastica de vacunas y enzimas geneticas.
JP3399518B2 (ja) * 1999-03-03 2003-04-21 インターナショナル・ビジネス・マシーンズ・コーポレーション 半導体構造およびその製造方法
EP1161529A2 (de) * 1999-03-09 2001-12-12 Diversa Corporation Selektion am ende in gezielter evolution
US6251604B1 (en) 1999-08-13 2001-06-26 Genopsys, Inc. Random mutagenesis and amplification of nucleic acid
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
AU2001241939A1 (en) * 2000-02-28 2001-09-12 Maxygen, Inc. Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
EP1276861A2 (de) * 2000-03-24 2003-01-22 Maxygen, Inc. Methoden zur modulation zellulärer und organismenspezifischer phenotypen
DK2199393T3 (da) * 2000-04-17 2012-11-26 Dyax Corp Hidtil ukendte fremgangsmåder til opbygning af biblioteker over genetiske pakker, der kollektivt viser medlemmerne af en forskelligartet familie af peptider, polypeptider eller proteiner
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
CA2411139A1 (en) * 2000-06-08 2001-12-13 James T. Willerson Inhibitors of c-reactive protein induced inflammation
FR2813314B1 (fr) * 2000-08-25 2004-05-07 Biomethodes Procede de mutagenese dirigee massive
WO2005012515A2 (en) 2003-04-29 2005-02-10 Pioneer Hi-Bred International, Inc. Novel glyphosate-n-acetyltransferase (gat) genes
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
PT2316940E (pt) 2000-12-18 2013-10-16 Dyax Corp Bibliotecas orientadas de pacotes genéticos
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
WO2002092780A2 (en) * 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20040096826A1 (en) * 2002-01-30 2004-05-20 Evans Glen A. Methods for creating recombination products between nucleotide sequences
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
US20030171543A1 (en) * 2002-03-05 2003-09-11 Bott Richard R. High throughput mutagenesis screening method
US20030199068A1 (en) * 2002-03-05 2003-10-23 Bott Richard R. High throughput mutagenesis screening method
WO2003089671A1 (en) * 2002-04-17 2003-10-30 Roberto Crea 'doping' in walk-through mutagenesis
DE60328674D1 (de) * 2002-04-17 2009-09-17 Bioren Inc Universelle banken für immunoglobuline
ES2285118T5 (es) * 2002-05-17 2012-09-21 Alligator Bioscience Ab Un método para el desarrollo molecular in vitro de una función proteica.
EP2275536A1 (de) 2002-08-06 2011-01-19 Verdia, Inc. AP1-Aminoxidase-Varianten
EP2269618A1 (de) 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Ein onkolytisches Vaccinia-Virus zur Verwendung in Kombination mit Chemotherapie zur Behandlung von Krebs
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7785799B2 (en) * 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
US20050118154A1 (en) 2003-04-02 2005-06-02 Mien-Chie Hung Antitumor effect of mutant Bik
WO2005003345A2 (en) * 2003-06-27 2005-01-13 R. Crea & Co. Look-through mutagenesis
EP2325339A3 (de) 2003-09-09 2011-11-02 Integrigen, Inc. Verfahren und zusammensetzungen zur Erzeugung menschlicher keimlinien-Antikörpergene
MX2007000103A (es) 2004-07-06 2007-05-11 Bioren Inc Bibliotecas de anticuerpos universales.
WO2006023144A2 (en) 2004-07-06 2006-03-02 Bioren Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
CA2573259A1 (en) * 2004-07-06 2006-02-09 Bioren Inc. High affinity anti-tnf-alpha antibodies and method
EP1877441A2 (de) * 2005-04-26 2008-01-16 Bioren, Inc. Verfahren zur herstellung von antikörpern gegen humanes igg mit verbesserten effektorfunktionen
US20070026012A1 (en) 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
KR20090004839A (ko) * 2005-09-07 2009-01-12 제네렉스, 인코포레이티드 Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
CA2627075A1 (en) 2005-11-14 2007-05-18 Bioren, Inc. Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
AU2007249160B2 (en) 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
US20080108513A1 (en) * 2006-06-01 2008-05-08 Northwestern University Cellular Arrays
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2064229B1 (de) 2006-09-15 2015-08-12 Ottawa Hospital Research Institute Onkolytisches rhabdovirus
MX2009004221A (es) 2006-10-20 2009-09-10 Univ Arizona State Cianobacterias modificadas.
US20090118130A1 (en) * 2007-02-12 2009-05-07 Codexis, Inc. Structure-activity relationships
US20100106585A1 (en) * 2007-04-17 2010-04-29 American Express Travel Related Services Company, Inc. System and method for evaluating positive behavior and offering incentives based upon limited use identifier transactions
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
BRPI0816785A2 (pt) * 2007-09-14 2017-05-02 Adimab Inc bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
US9873957B2 (en) 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
CA2722409C (en) 2008-04-24 2017-12-12 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
ES2620285T3 (es) 2008-05-02 2017-06-28 Novartis Ag Moléculas de unión con base en fibronectina mejorada y usos de las mismas
ES2752025T3 (es) 2008-07-25 2020-04-02 Wagner Richard W Métodos de cribado de proteínas
JP5230397B2 (ja) * 2008-12-18 2013-07-10 独立行政法人科学技術振興機構 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法
US8987433B2 (en) 2009-03-27 2015-03-24 Sapphire Energy, Inc. Variant isoprenoid producing enzymes and uses thereof
JP5647222B2 (ja) 2009-04-10 2014-12-24 アブリンクス エン．ヴェー． Ｉｌ−６ｒ関連疾患及び障害の治療のためのｉｌ−６ｒに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US8945567B2 (en) 2009-06-05 2015-02-03 Ablynx N.V. Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
CN107303302A (zh) 2009-09-14 2017-10-31 希拉金股份有限公司 溶瘤牛痘病毒组合癌症疗法
AU2010291902A1 (en) * 2009-09-14 2012-04-05 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
EP3434769B1 (de) 2009-10-30 2020-11-25 Novartis AG Unterseitig bindende universelle fibronectin-typ-iii-domänenbibliotheken
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
EP2507262A1 (de) 2009-11-30 2012-10-10 Ablynx N.V. Verbesserte gegen hrsv gerichtete aminosäuresequenzen und polypeptide damit zur prävention und/oder behandlung von atemwegsinfektionen
MX337062B (es) 2009-12-10 2016-02-11 Ottawa Hospital Res Inst Rabdovirus oncolítico.
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
EP3741883B1 (de) 2010-07-16 2022-12-14 Adimab, LLC Antikörperbibliotheken
EP2598529A2 (de) 2010-07-30 2013-06-05 Novartis AG Fibronectin-cradle-moleküle und bibiotheken
CA2805941A1 (en) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Methods and compositions for targeting sequences of interest to the chloroplast
KR101942237B1 (ko) 2011-01-04 2019-01-25 신라젠(주) 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
EP2718427B1 (de) 2011-06-08 2017-01-11 Children's Hospital of Eastern Ontario Research Institute Inc. Zusammensetzungen zur behandlung von glioblastomen
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
RU2019133467A (ru) 2011-10-11 2020-07-06 МЕДИММЬЮН, ЭлЭлСи Cd40l-специфичные каркасные структуры, происходящие из tn3, и способы их применения
MX2014010495A (es) 2012-03-02 2014-11-14 Ablynx Nv Polipeptidos que enlazan a pcrv.
CA2872096A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CA2901501C (en) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
WO2014153242A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
WO2014153234A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
WO2016062766A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
EP3268389B1 (de) 2015-03-12 2020-09-30 Medimmune, LLC Verfahren zur aufreinigung von albuminfusionsproteinen
JP6962819B2 (ja) 2015-04-10 2021-11-05 アディマブ， エルエルシー 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
WO2016187101A2 (en) 2015-05-21 2016-11-24 Full Spectrum Genetics, Inc. Method of improving characteristics of proteins
CA3028002A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
WO2018237323A1 (en) 2017-06-23 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University DOMAINS OF DETABILIZATION OF PDE5A
MA51154A (fr) 2017-12-15 2020-10-21 Aleta Biotherapeutics Inc Variants de cd19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130597A (ja) * 1984-07-20 1986-02-12 Nippon Zeon Co Ltd ポリヌクレオチド合成装置
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
EP0417165B1 (de) * 1988-05-11 1994-01-26 Polygen Holding Corporation Polypeptid-verbindungen mit hormonwachstumsbefreiender wirkung
IL91501A (en) * 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US6780613B1 (en) * 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
FI87028C (fi) * 1989-12-22 1992-11-10 Nokia Mobile Phones Ltd Metod foer att reglera effekt hos en spaenningsstyrd effektfoerstaerkare och koppling foer anvaendning i metoden
US5264563A (en) * 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons

Also Published As

Publication number Publication date
DE69112207T2 (de) 1996-03-28
JPH05506580A (ja) 1993-09-30
JP4275922B2 (ja) 2009-06-10
EP0527809B1 (de) 1995-08-16
ES2078518T3 (es) 1995-12-16
AU7741891A (en) 1991-10-30
CA2079802A1 (en) 1991-10-06
JP2003135084A (ja) 2003-05-13
JP4251406B2 (ja) 2009-04-08
AU653152B2 (en) 1994-09-22
US6649340B1 (en) 2003-11-18
WO1991015581A1 (en) 1991-10-17
US5830650A (en) 1998-11-03
ATE126535T1 (de) 1995-09-15
CA2079802C (en) 2001-09-18
US5798208A (en) 1998-08-25
EP0527809A1 (de) 1993-02-24

Similar Documents

Publication Publication Date Title
DE69112207D1 (en) "walk-through"-mutagenese.
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
WO2005003345A3 (en) Look-through mutagenesis
NO913186D0 (no) Fremgangsmaate for anvendelse og syntese av peptider.
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
ES2078907T3 (es) Metodo para radiomarcar proteinas.
EP0355460A3 (de) Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
ATE121752T1 (de) Entfernung von protein a aus antikörper- präparationen.
FR2705341B1 (fr) Procédé de préparation de mélanges d'acides aminés N-acylés, mélanges d'acides alpha aminés N-acylés, et leurs utilisations.
DE68903576D1 (de) Signalpeptide, die in hefe wirksam sind und ihre verwendung zur sekretorischen expression von heterologen proteinen.
FI945877A0 (fi) Menetelmä proteiini C:n tuottamiseksi
ES2109225T3 (es) Anticuerpos, su produccion y uso.
IL91475A0 (en) Production of gonadotropin superagonists by recombinant dna methods and said super agonists produced thereby
CA2004387A1 (en) Cyclosporine binding protein and use in an assay for biologically-active cyclosporine
KR900007299A (ko) 고농도배양에 의한 단세포단백질의 제조방법
DK623089A (da) Trombolytiske proteiner, fremgangsmaade til fremstilling deraf og praeparater indeholdende disse forbindelser
HUT37109A (en) Process for the phosphinoylation of amino gropus of amino-acids, peptides and esters thereof
Bitt et al. Amino acid analysis of culture media and autolyzates by the method of capillary gas chromatography.
CS555888A1 (en) Method of pure specific antibodies production for proteins concentration's quick quantitative determination
DE3888078T2 (de) Veränderungsverfahren für Peptide und Proteine.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOREN, INC. (N.D.GES.D. STAATES DELAWARE), SA, US

8381 Inventor (new situation)

Inventor name: CREA, ROBERTO, CHESTNUT HILL, MASS., US